Click to view this email in a browser  |  Forward this message to a friend
A complimentary accredited Webinar:
Influenza Testing and the FDA Reclassification: Where Do We Go from Here?
Date: Wednesday, June 6, 2018
Time: 1:00 - 2:00 PM EST
This webinar is produced by Whitehat Communications
and sponsored by Fisher Healthcare
Gray line 300x1 3
FDA Influenza Reclassification went into full effect in January 2018.  This change placed additional requirements on influenza lateral flow assay manufactures. As a result, some assays were removed from the market.

This change in influenza assay availability challenged some testing facilities to adjust their assay use, or to purchase excess inventory for the 2017/2018 influenza season. Now that the 2017/2018 influenza season has passed, testing facilities that did not implement an FDA-approved test will need determine their influenza testing plans for the 2018/2019 influenza season and beyond.

This educational webinar will review flu testing challenges faced during the 2017/2018 influenza season, including discussion on the management and mitigation of highly seasonal testing and a review of testing options for the 2018/2019 season. The session will also analyze the pros and cons of each type of influenza testing.
This webinar will:
  • Review FDA Influenza Reclassification Requirements to provide understanding of changes following the January 2018 enforcement date
  • Identify the different types of influenza tests available, following FDA Influenza Reclassification
  • Analyze the pros and cons of each type of influenza testing
  • Discuss the 2017/2018 influenza season and lessons learned to prepare for future seasons
Gray line 300x1 2
The presenter
  Greg-Berry-Photo-100x135 Gregory J. Berry, Ph.D., D(ABMM)
Director, Molecular Diagnostics
Assistant Director, Division of Infectious Disease Diagnostics
Northwell Health Laboratories

Gregory J. Berry Ph.D., D(ABMM) is a Diplomate of the American Board of Medical Microbiology and an Assistant Professor of Pathology and Laboratory Medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. He is also the Director of Molecular Diagnostics and an Assistant Director of Infectious Disease Diagnostics at Northwell Health Laboratories in New York.
  Continuing education credit:
  • 1 P.A.C.E.® credit-hour will be provided for this complimentary basic level program.
    Whitehat Communications is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program.
  • This session is approved for 1 Florida Laboratory CE credit. Florida Board of Clinical Laboratory Personnel approved number: 50-12563
This webinar is sponsored by Fisher Healthcare.
Fisher-Healthcare-logo-300x137-091817 2
©2018 Fisher Healthcare

Click to view this email in a browser

If you no longer wish to receive these emails, please reply to this message with "Unsubscribe" in the subject line or simply click on the following link: Unsubscribe

Whitehat Communications
2220 Ivy Rd
Charlottesville, Virginia 22903